New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 10, 2014
10:26 EDTBHI, PSUN, MXIM, JNJ, LNG, TPH, SLB, PFE, LVS, FNP, BLK, UIS, TDG, SI, OHI, KIM, LLY, EV, BP, ATI, BMRNOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Allegheny Technologies (ATI) downgraded to Hold from Buy at Deutsche Bank... BP (BP) downgraded to Neutral from Outperform at Exane BNP Paribas... BioMarin (BMRN) downgraded to Equal Weight from Overweight at Barclays... BlackRock (BLK) downgraded to Neutral from Buy at Goldman... Cheniere Energy (LNG) downgraded to Neutral from Buy at Citigroup... Eli Lilly (LLY) downgraded to Underweight from Equal Weight at Barclays... Fifth & Pacific (FNP) downgraded to Hold from Buy at Brean Capital... Johnson & Johnson (JNJ) downgraded to Equal Weight from Overweight at Barclays... Kimco Realty (KIM) downgraded to Sell from Neutral at UBS... Las Vegas Sands (LVS) downgraded to Market Perform from Outperform at FBR Capital... Maxim Integrated (MXIM) downgraded to Perform from Outperform at Oppenheimer... Omega Healthcare (OHI) downgraded to Sell from Neutral at UBS... Pacific Sunwear (PSUN) downgraded to Neutral from Buy at Janney Capital... Pfizer (PFE) downgraded to Market Perform from Outperform at Cowen... Siemens (SI) downgraded to Neutral from Buy at BofA/Merrill... Schlumberger (SLB) downgraded to Sector Perform from Outperform at Iberia... Baker Hughes (BHI) downgraded to Sector Perform from Outperform at Iberia... TransDigm (TDG) downgraded to Neutral from Buy at DA Davidson... TRI Pointe Homes (TPH) downgraded to Market Perform from Outperform at FBR Capital... Eaton Vance (EV) downgraded at Susquehanna... Unisys (UIS) downgraded to Neutral from Positive at Susquehanna.
News For ATI;BP;BMRN;BLK;LNG;LLY;FNP;JNJ;KIM;LVS;MXIM;OHI;PFE;PSUN;SI;SLB;BHI;TDG;TPH;EV;UIS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>
December 9, 2014
06:05 EDTLNGStocks with implied volatility movement; LNG OXY
Stocks with implied volatility movement; Cheniere Energy (LNG) 59, Occidental Petroleum (OXY) 33 according to iVolatility.
05:50 EDTJNJPharmacyclics data demonstrates safety, durability response
New, 27-month IMBRUVICA median follow-up data announced by Pharmacyclics (PCYC) support the use of IMBRUVICA over longer periods of time in patients with relapsed/refractory mantle cell lymphoma, or MCL, an aggressive type of lymphoma. More than 30% of IMBRUVICA patients remained progression-free after two years with no new or unexpected adverse events occurring during that time. Nearly half of the 111 patients treated were still living at the time of the data analysis. A second Phase II trial looked at IMBRUVICA's efficacy and safety as a single-agent treatment for MCL patients who previously had received rituximab combination therapy and at least two cycles of bortezomib. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:50 EDTSLBSchlumberger downgraded to Hold from Buy at Jefferies
Subscribe for More Information
05:43 EDTJNJPharmacyclics reports IMBRUVICA data shows 84% PFS rate at one year
Pharmacyclics (PCYC) announced new, longer term data in IMBRUVICA patients with relapsed/refractory chronic lymphocytic leukemia, or CLL, including high-risk CLL patients with deletion 17p. Results from the Phase III RESONATE trial demonstrated an 84% progression-free survival, or PFS, rate in all patients with previously treated CLL or small lymphocytic lymphoma, or SLL, who received IMBRUVICA and a 94% PFS rate in patients who received only one prior therapy at 12 months. Separately, follow-up data was reported from Phase II RESONATE-17, or PCYC-1117, the largest prospective trial dedicated to studying CLL or SLL patients with del 17p. The data showed that IMBRUVICA was associated with an 83% overall response rate, or ORR, at a median follow up of 11.5 months. At 12 months, the estimated PFS was 79%. These results and additional data were presented here at the 56th American Society of Hematology, or ASH, Annual Meeting, highlighting IMBRUVICA's sustained efficacy in relapsed/refractory patients who have received at least one prior therapy. IMBRUVICA combination therapy resulted in an 88% overall response rate in MCL patients with a complete response rate of 40%. IMBRUVICA is jointly developed and commercialized by Pharmacyclics and Janssen Biotech, a unit of Johnson and Johnson (JNJ).
05:27 EDTJNJPharmacyclics IMBRUVICA Phase II combination data shows positive profile
Subscribe for More Information
December 8, 2014
13:32 EDTPFEPfizer, Bristol-Myers announce results of human study on Eliquis
Bristol-Myers Squibb Company (BMY) and Pfizer (PFE) announced results of the first human study evaluating the reversal of the anticoagulant effect of Eliquis by 4-factor prothrombin complex concentrates in healthy subjects. The study results demonstrated that both PCCs, Sanquin’s Cofact and CSL Behring’s Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis in several coagulation assessments, including endogenous thrombin potential. The full data will be presented today during the Antithrombotic Therapy: Anticoagulant Therapy session at the 56th annual meeting of the American Society of Hematology in San Francisco, CA. The study was an open label, randomized, placebo-controlled, three-period crossover study in 15 healthy, adult subjects. Within each period, subjects received Eliquis 10 mg twice daily. On day four, three hours after Eliquis administration, subjects received a 30-minute infusion of 4-factor PCCs, either 50 IU/kg Cofact or Beriplex P/N, or an equivalent volume of saline solution. The effect of Cofact and Beriplex P/N on the pharmacodynamics of Eliquis was based upon changes in endogenous thrombin potential, a measure of thrombin-mediated coagulation. Treatment periods were separated by an 11-day washout, after which the alternate treatment was administered. In this study, no serious adverse events, bleeding-related events or signs of thrombosis were reported with Eliquis administration with or without PCC treatment. Overall, these data demonstrate that Cofact and Beriplex P/N reversed the steady-state pharmacodynamic effects of Eliquis as measured by ETP and support further evaluation of PCCs in the management of patients treated with Eliquis who require reversal of its anticoagulant effect.
10:53 EDTBPBP to continue advocating for probe of suspicious, implausible spill claims
Subscribe for More Information
10:11 EDTBPBP's plea to review Deepwater Horizon settlement rejected, WSJ reports
Subscribe for More Information
10:00 EDTBLKOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
10:00 EDTOHIOn The Fly: Analyst Upgrade Summary
Today's noteworthy upgrades include: Antero Resources (AR) upgraded to Buy from Neutral at Citigroup... Apache (APA) upgraded to Buy from Neutral at Citigroup... Applied Materials (AMAT) upgraded to Buy from Hold at Deutsche Bank... Arch Capital (ACGL) upgraded to Outperform from Market Perform at BMO Capital... CU Bancorp (CUNB) upgraded to Buy from Hold at Sandler O'Neill... Calpine (CPN) upgraded to Outperform from Neutral at Macquarie... Commerzbank (CRZBY) upgraded to Market Perform from Underperform at Keefe Bruyette... EastGroup Properties (EGP) upgraded to Neutral from Underperform at Credit Suisse... Enbridge Energy Management (EEQ) upgraded to Equal Weight at Morgan Stanley... Enbridge Energy (EEP) upgraded to Equal Weight from Underweight at Morgan Stanley... GasLog (GLOG) upgraded to Buy from Hold at Stifel... Hoegh LNG (HMLP) upgraded to Buy from Neutral at UBS... Illinois Tool Works (ITW) upgraded to Buy from Accumulate at Global Hunter... LaSalle Hotel (LHO) upgraded at Morgan Stanley... Lufthansa (DLAKY) upgraded to Buy from Neutral at Nomura... NASDAQ (NDAQ) upgraded to Outperform from Market Perform at Keefe Bruyette... Newfield Exploration (NFX) upgraded to Buy from Neutral at Citigroup... Omega Healthcare (OHI) upgraded to Buy from Hold at Jefferies... Orange SA (ORAN) upgraded to Conviction Buy from Neutral at Goldman... SM Energy (SM) upgraded to Outperform from Market Perform at BMO Capital... Southwest (LUV) upgraded at Goldman... TSMC (TSM) upgraded to Buy from Neutral at BofA/Merrill... United Technologies (UTX) upgraded at Bernstein... eBay (EBAY) upgraded to Buy from Hold at Stifel.
09:27 EDTBLKBlackRock downgraded to Neutral at Susquehanna
As previously reported, Susquehanna downgraded BlackRock to Neutral from Positive citing weaker emerging markets and reduced expectations for active equity flow in 2015. Susquehanna maintained its $365 price target on BlackRock shares.
08:10 EDTLLYLilly, Anthem, HealthCore form five-year research collaboration
Eli Lilly and Company (LLY), Anthem (ANTM) and HealthCore, Inc. announced that they have formed a five-year, real-world evidence research collaboration intended to improve health outcomes for patients. The companies will jointly develop and conduct research projects in health outcomes and real-world evidence in areas of mutual interest. Each party will bring distinct and valuable contributions to the collaboration, including the U.S. provider and patient environment, research capabilities, therapeutics and methods expertise, and integrated, researchable data. The collaboration allows the organizations to explore research opportunities across disease states and incorporate surveys and other information from providers and patients.
08:03 EDTPFEPfizer announces agreement with Spark Therapeutics to develop SPK-FIX
Subscribe for More Information
07:53 EDTBPClimate for Exxon E&P acquisition improved by falling prices, WSJ says
Subscribe for More Information
07:32 EDTMXIMRaymond James to hold a conference
Subscribe for More Information
07:03 EDTBLKBlackRock downgraded to Neutral from Positive at Susquehanna
Subscribe for More Information
06:09 EDTBPBP to cut hundreds of U.K. jobs this week, Guardian reports
Subscribe for More Information
05:56 EDTOHIOmega Healthcare upgraded to Buy from Hold at Jefferies
Subscribe for More Information
December 7, 2014
19:41 EDTBPBP set to reduce middle management ranks, freeze projects, Sunday Times says
Subscribe for More Information
14:54 EDTJNJIMBRUVICA data suggests promise in multiple myeloma
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use